346 related articles for article (PubMed ID: 9708683)
21. Variable influence of statins on isoprostanes in hyperlipidemia.
Sinzinger H; Oguogho A
Adv Exp Med Biol; 2003; 525():209-12. PubMed ID: 12751770
[No Abstract] [Full Text] [Related]
22. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
23. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
24. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Asztalos BF; Horvath KV; McNamara JR; Roheim PS; Rubinstein JJ; Schaefer EJ
Atherosclerosis; 2002 Oct; 164(2):361-9. PubMed ID: 12204809
[TBL] [Abstract][Full Text] [Related]
25. [Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
MMW Fortschr Med; 2004 Mar; 146(13):64-5. PubMed ID: 15219142
[No Abstract] [Full Text] [Related]
26. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Bakker-Arkema RG; Nawrocki JW; Black DM
Atherosclerosis; 2000 Mar; 149(1):123-9. PubMed ID: 10704623
[TBL] [Abstract][Full Text] [Related]
27. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Doggrell SA
Rev Recent Clin Trials; 2006 May; 1(2):143-53. PubMed ID: 18473965
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
29. [Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
MMW Fortschr Med; 2004 Oct; 146(44):57. PubMed ID: 15566254
[No Abstract] [Full Text] [Related]
30. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
31. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Wierzbicki AS; Mikhailidis DP
Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM
Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621
[TBL] [Abstract][Full Text] [Related]
33. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
[TBL] [Abstract][Full Text] [Related]
34. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
35. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
Jacotot B; Benghozi R; Pfister P; Holmes D
Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of atorvastatin in heart transplant recipients.
Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
38. Lowering effects of four different statins on serum triglyceride level.
Branchi A; Fiorenza AM; Rovellini A; Torri A; Muzio F; Macor S; Sommariva D
Eur J Clin Pharmacol; 1999 Sep; 55(7):499-502. PubMed ID: 10501818
[TBL] [Abstract][Full Text] [Related]
39. [For coronary disease patients is certain: the lower the LDL the better].
MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
[No Abstract] [Full Text] [Related]
40. Statin therapy--what now?
Drug Ther Bull; 2001 Mar; 39(3):17-21. PubMed ID: 11284361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
